Drugs.com - New Drug Approvals

Mirum’s Livmarli Now FDA Approved in Tablet Formulation

FOSTER CITY, Calif.--(BUSINESS WIRE) April 14, 2025 -- Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today announced that the U.S. Food and Drug Administration (FDA) has approved a new tablet formulation of Livmarli (maralixibat) for the treatment of...

Apr 15, 2025 - 01:42
 0
Mirum’s Livmarli Now FDA Approved in Tablet Formulation
FOSTER CITY, Calif.--(BUSINESS WIRE) April 14, 2025 -- Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today announced that the U.S. Food and Drug Administration (FDA) has approved a new tablet formulation of Livmarli (maralixibat) for the treatment of...
Read More

Tags:

Previous Article

Burnout Is Killing Climate Progress—Here’s How We Fix It

Next Article

Australian Gold and Copper: Strategic Exploration, Strong Cash & Achilles Potential

Related Posts

Galderma Receives U.S. FDA Approval for Nemluvio (nemolizumab) for Patients with Moderate-to-Severe Atopic Dermatitis

Galderma Receives U.S. FDA Approval for Nemluvio (nemol...

Feb 9, 2025  0

FDA Approves Bomyntra (denosumab-bnht), a Biosimilar to Xgeva

FDA Approves Bomyntra (denosumab-bnht), a Biosimilar to...

Mar 29, 2025  0

FDA Approves Datroway (datopotamab deruxtecan-dlnk) for Patients with Previously Treated Metastatic HR Positive, HER2 Negative Breast Cancer

FDA Approves Datroway (datopotamab deruxtecan-dlnk) for...

Feb 9, 2025  0